INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron.
From the U.S. FDA-approved label for Iron dextran. Full label: DailyMed.
INFeD is indicated for treatment of adult and pediatric patients of age 4 months and older with documented iron deficiency who have intolerance to oral iron or have had an unsatisfactory response to oral iron.
From the U.S. FDA-approved label for Iron dextran. Full label: DailyMed.
See Full Prescribing Information for weight-based dosing and administration information. Weight in Kg Weight in Kg INFeD dose volume 2.1 Important Pre-Treatment Information Discontinue administration of any iron-containing products prior to administration of INFeD. Assess baseline hematologic (hemoglobin and hematocrit) and iron storage parameters (serum iron, total iron binding capacity, and percent saturation of transferrin) to monitor response to therapy.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
INFeD is contraindicated in patients who have demonstrated a previous hypersensitivity to iron dextran. Known hypersensitivity to INFeD
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Delayed Reactions: May occur with large intravenous doses. Increased Risk of Toxicity in Patients with Underlying Conditions: Monitor for toxicity in these patients. Iron Overload: Excessive therapy can lead to iatrogenic hemosiderosis. Do not administer to patients with iron overload. Periodically monitor hematologic and iron parameters. 5.1 Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported following the parenteral administration of iron dextran products, including INFeD.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Delayed Reactions Increased Risk of Toxicity in Patients with Underlying Conditions Iron Overload Fetal bradycardia The following adverse reactions associated with the use of INFeD were identified in clinical studies or postmarketing reports.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
2 Stability and Storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F)..
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
